



MGFA 15th International Conference on Myasthenia Gravis and Related Disorders
The Hague, The Netherlands
May 13th-15th, 2025

Submission Requirements

- All abstract information must be submitted by November 15, 2024, 5 pm EST.
- Abstracts are submitted via Proposal Central at www.proposalcentral.com.
- Abstracts must contain the following for each author: full name, affiliation name, country, and disclosures.

Important Dates

- September 1, 2024: Abstracts open for submission
November 15, 2024: Abstracts submission closes
January 15, 2025: Primary authors receive email with acceptance decision
March 15, 2025: Primary author meeting registration Deadline
May 13-15, 2025: 2025 International Meeting on Myasthenia and Related Disorders, The Hague, The Netherlands

Abstract Authors

- All abstract authors must be listed at the time of submission.
Authors cannot be added after the abstract has been submitted.
- Primary/presenting authors are required to register for and attend the conference to present their poster
- Only the primary author will receive communication about the abstract. It is their responsibility to share the information with co-authors.
- Pharmaceutical employees can be part of the research team on an abstract, however, it is encouraged that a physician present the abstract

Abstract Format

- The maximum word count for abstracts, not including the title, is 300 words
Abstracts should be entered in one of three categories:

Basic Science
Clinical Science
Translational Science

- No references should be cited or included in the abstract
- Images, illustrations, and references are not allowed in abstracts but can be included in posters
- Abbreviations should not be used in the title of the abstract and should be used minimally in text
- Only use abbreviations related to MG (MG, MuSK, AChR, LRP4, etc) ;When using other abbreviations; spell out the full version followed by the abbreviation in parentheses
Example: amyotrophic lateral sclerosis (ALS)
- Do not submit abstracts written in all CAPS
- When referring to name-brand drugs, the generic name must be provided
- It is recommended that you write and edit your abstract in the template provided, then cut and paste into the online submission form.



Late-Breaking Abstracts

MGFA reserves the right to accept late-breaking abstracts, but does not guarantee this opportunity based on initial submissions. It is strongly encouraged to submit within the original submission window.

Encore Abstracts Applications for poster or platform presentations are acceptable even if the data has been previously presented, so long as it has never been published in manuscript form in a peer-reviewed journal, prior to the meeting.

Abstract Decisions

All abstract decisions made by the Abstract Review Committee are final.

Poster Guidelines

- Poster display boards are size A0 in landscape (84.1 cm x 118.9 cm or 33.1 in x 46.8 in); posters should not exceed this size
- Posters may contain graphs, charts, illustrations, and references
- All author disclosures must be included on the poster
- There is no audio-visual equipment capability in the poster hall
- QR codes can be used on posters to provide additional information to attendees.

Poster Presentations

About one month before the meeting, you will receive an email with your assigned poster location and presentation times.

Meeting Attendance

Abstract authors agree to register and pay for the conference as a condition of abstract submission. Primary authors are required to attend the meeting and be present with their poster during the assigned presentation times. If the person who was originally planning to attend the meeting is unable to do so, another author must be designated to take their place.

Questions?

Contact MGFA at mgfa@myasthenia.org; copy lchandler@myasthenia.org

To visit conference event page, scan below.

